Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis

Area of Science:

• Immunology
• Cardiology
• Pharmacology

Background:

• Experimental autoimmune myocarditis (EAM) is an immune-mediated cardiac disease.
• Dipeptidyl peptidase-4 (DPP-4) is implicated in inflammatory processes.
• Understanding DPP-4's role in EAM is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the mechanism by which DPP-4 inhibition ameliorates EAM.
• To investigate the interaction between DPP-4 and cathepsin G in the context of EAM.
• To assess the effect of linagliptin on Th17 cell infiltration and oxidative stress in EAM.

Main Methods:

• Administration of linagliptin to EAM model.
• Flow cytometry to quantify Th17 cells.
• Tandem mass spectrometry to analyze protein interactions.
• Assessment of oxidative stress markers.

Main Results:

• Linagliptin treatment significantly attenuated Th17 cell infiltration in the EAM myocardium.
• DPP-4 was found to bind cathepsin G in EAM hearts, inhibiting SerpinA3N activity.
• Linagliptin suppressed oxidative stress in EAM hearts.

Conclusions:

• DPP-4 plays a detrimental role in EAM progression through interaction with cathepsin G.
• Inhibition of DPP-4 by linagliptin offers a potential therapeutic strategy for EAM.
• Linagliptin ameliorates EAM by reducing inflammatory cell infiltration and oxidative stress.